Attention-deficit/hyperactivity disorder: increased costs for patients and their families

Area of Science:

• Health Economics
• Pediatric Health
• Mental Health Research

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in children.
• The economic impact of ADHD extends beyond direct medical costs to include indirect costs like work loss.
• Understanding the financial burden on families is crucial for comprehensive care and support.

Purpose of the Study:

• To quantify the direct medical and prescription drug costs associated with treating pediatric ADHD.
• To estimate the indirect costs, specifically work loss, for children with ADHD and their families.
• To compare the total economic burden of ADHD patients and their families against a control group.

Main Methods:

• Utilized an administrative claims database from a national manufacturer (over 100,000 beneficiaries).
• Analyzed four samples: ADHD patients (≤18 years), matched non-ADHD controls, non-ADHD family members of ADHD patients, and matched family controls.
• Compared resource utilization and costs between ADHD and control groups from 1996-1998.

Main Results:

• Annual direct costs per ADHD patient averaged $1,574, versus $541 for controls.
• Annual total costs (direct and indirect) per family member averaged $2,728 for families of ADHD patients, compared to $1,440 for control families.
• Both patient and family cost differences were statistically significant (95% confidence level).

Conclusions:

• Pediatric ADHD presents a substantial financial burden on healthcare systems and families.
• The economic impact includes significant direct costs for medical care and indirect costs from work loss.
• ADHD necessitates considerable financial resources for both affected children and their family members.